Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 108.0 Kadcyla (ado-trastuzumab emtansine)
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate.
MBP 86.0 Kalbitor (ecallantide)
Kalbitor (ecallantide) is a human plasma kallikrein inhibitor produced in Pichia pastoris yeast cells by recombinant DNA technology.
MBP 119.0 Keytruda (pembrolizumab)
Keytruda (pembrolizumab) binds to the programmed death receptor-1 (PD-1) ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production.
MBP 159.0 Kymriah (tisagenlecleucel)
Kymriah (tisagenlecleucel) is a CD19-directed genetically modified autologous T cell immunotherapy in which a patient's T cells are reprogrammed with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells.
New Policy 11/21/17
MBP 97.0 Kyprolis (carfilzomib)
Kyprolis (carfilzomib) is a tetrapeptide epoxyketone protease inhibitor that irreversibly binds to the N-terminal threonine – containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.